Skip to main content
News & Press Releases

Imagin Medical Announces PP for Communications

By 26 October 2017August 11th, 2022No Comments

Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in detecting cancers and visualizing the surgical field in minimally invasive surgery. The Company’s initial focus is bladder cancer. 

Vancouver, B.C. and Boston, MA, October 26, 2017 – Imagin Medical, Inc. (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the “Company”) announces it is closing a $120,000 financing to raise funds to be used for the Company’s communications program (the “Financing”). This financing will not be oversubscribed. The Company is committed to continuing the development of the i/Blue Imaging System for the detection of bladder cancer and keeping its shareholders informed of its progress. 

The funds raised pursuant to the Financing will be specifically targeted for a communications and marketing program, allowing the Company to continue to maintain its existing cash for product development and commercialization. The Financing will consist of 800,000 units (the “Units”) at a price of $0.15 per Unit, each Unit to be comprised of one common share and one half of one common share purchase warrant (the “Warrants”). Each whole Warrant will be exercisable into one common share in the equity of the Company (the “Warrant Shares”) at an exercise price of $0.25 per Warrant Share. The Warrants expire one year from date of issuance. 

About Imagin Medical 

Imagin Medical is developing imaging solutions for minimally invasive surgical procedures where endoscopes are used. The Company believes it will radically improve the way physicians detect cancer and view the surgical field. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. The ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at 

For further information, contact: 

Jim Hutchens, President & CEO
Telephone: 617-571-6006
Email: [email protected]

Information set forth in this news release contains forward-looking statements. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual and future events, conditions, and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Company’s imaging system will work in the manner expected, except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.